Committed Investment: March, 2018
Status: Active Portfolio Company
CMXTwenty (Milwaukee) is a pharmaceutical company positioned to address the opioid crisis. The company is focused on developing a non-narcotic treatment for pain using a unique lipid molecule called CMX-020. In 2020, CMXTwenty focused on animal studies to prepare for a proof-of-concept in dental pain. Success in this study could pave the way to phasing out of opioid therapeutics around the world.